Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy ...
Managed Healthcare Executive

Phase 3 trial program begins for investigational sleep medication, alixorexton

Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy of alixorexton compared with placebo in adults, according to a news release.

Why do 'sleep attacks' happen? Study points to an autoimmune trigger in narcolepsy

Researchers at the Netherlands Institute for Neuroscience have found evidence that type-1 narcolepsy, a condition known for ...
Business Insider

Do you have narcolepsy? Take this test to screen for symptoms of excessive daytime sleepiness

Narcolepsy is a rare condition that will make someone fall asleep abruptly — even in the middle of the day during an activity. It's possible to treat narcolepsy and manage your symptoms with ...
MedPage Today

Narcolepsy-CVD Link: Stage Is Set as Early as Childhood

Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy ...
Daily Journal

Lilly to acquire UK-based pharmaceutical company in deal worth up to $7.8B

Eli Lilly and Co. announced Tuesday that it will spend up to $7.8 billion to acquire a United Kingdom-based pharmaceutical ...